EDUCATION

Undergraduate:

Iowa State University

Ames, Iowa

Degree: BS, May 1977

Graduate:

University of Iowa College of Medicine

Iowa City, Iowa

Degree: MD, May 1981

Post Graduate Training:

Residency, Dermatology, 1982?1985

University of Cincinnati Medical Center

Cincinnati, Ohio

Chief Resident, Dermatology, 1984?1985

University of Cincinnati Medical Center

Cincinnati, Ohio

PROFESSIONAL CERTIFICATION

Diplomate ? American Board of Dermatology, 1985

Clinical Investigator Certification, 2002

Association of Clinical Research Professionals

LICENSURE

Ohio

PUBLICATIONS

Breneman DL, Lucky AW, Ostrow RS, Vogler C, Jenski JF: Bowenoid papulosis of the genitalia associated with human papillomavirus DNA type 16 in an infant with atopic dermatitis. Pediatr Dermatol 2(4):297?301, 1985.

Belz JL, Breneman DL, Nordlund JJ, Solinger AM: Successful treatment of a patient with Reiter's syndrome and AIDS using etretinate. J Am Acad Dermatol 20(5):898?903, 1989.

Breneman DL, Amornsiripanitch S, Barron DR, Peglow S, Bushong RL: Granulomatous secondary syphilis in a patient with human immunodeficiency virus infection. Cutis 44:377?381, 1989.

Fivenson DP, Breneman DL: A rapidly progressive papulovesicular eruption. Arch Dermatol 125(11):569?74, 1989.

Fivenson DP, Crump G, Scheele P, Breneman DL: Systemic lupus erythematosus developing in a patient with long?standing pulmonary sarcoidosis ? report of a case and review of the literature. J Rheumatol 16:1116?1119, 1989.

Breneman DL: Use of mupirocin ointment in the treatment of secondarily infected dermatoses. J Am Acad Dermatol 22(5):886?892, 1990.

Fivenson DP, Breneman DL, Wander AH: Kaposi's varicelliform eruption: absence of ocular involvement. Arch Dermatol 126:1037?1039, 1990.

Kalivas J, Breneman D, Tharp M, Bruce S, Bigby M: Urticaria: Clinical efficacy of cetirizine in comparison with hydroxyzine and placebo. J Allergy Clin Immunol 86:1014?1018, 1990.

Kleier RS, Breneman DL, Boiko S: Generalized pustulation as a manifestation of the anticonvulsant hypersensitivity syndrome. Arch Dermatol, 127:1361?1364, 1991.

Robinson MK, Parsell KW, Breneman DL, Cruze CA: Evaluation of the primary skin irritation and allergic contact sensitization potential of transdermal triprolidine. Fund Appl Toxicol, 17:103?119, 1991.

Supapannachart N, Breneman DL, Linnemann CC: Isolation of human immunodeficiency virus from cutaneous blister fluid in porphyria cutanea tarda. Arch Dermatol, 127:1198?1200, 1991.

Breneman DL, Like?Nartker A, Ballman EA, Pruemer JM, Blumsack RF, Davis M, Breneman JC: Topical mechlorethamine in the treatment of mycosis fungoides ? uniformity of distribution and potential for environmental contamination. J Am Acad Dermatol, 25:1059?1064, 1991.

Smith EB, Breneman DL, Griffith RF, Herbert AA, Hickman JG, Maloney JM, Millikan LE, Sulica VI, Dromgoole SH, Sefton J, DeGryse RE, Killey FP: Double?blind comparison of naftifine cream and clotrimazole/betamethasone dipropionate cream in the treatment of tinea pedis. J Am Acad Dermatol, 26:125?127, 1992.

Breneman DL, Cardone JS, Kauffman RF, Lather RM, Searle EA, Pollack VE: Topical capsaicin for the treatment of hemodialysis?related pruritus. J Am Acad Dermatol, 26:91?94, 1992.

Breneman DL, Davis M, Berger V, Chaney R: A double?blind trial comparing the efficacy and safety of augmented betamethasone diproprionate lotion to fluocinonide solution in the treatment of severe scalp psoriasis. J Dermatol Treat, 3:19?21, 1992.

Breneman DL, Hoppenjans WB: Scurvy in an alcoholic man. Clinical Cases in Dermatology, 4(4):2?5, 1992.

Breneman DL: Bath PUVA: An effective treatment for psoriasis without systemic side effects. Cosmetic Dermatology 5(3):52?53, 1992.

Foss FM, Ihde DC, Breneman DL, Phelps RM, Fischmann AB, Schechter GR, Linnoila I, Breneman JC, Cotelingam JD, Ghosh BC, Steinberg SM, Lynch JW, Phares JC, Stocker JL, Bastian A, Sausville EA: Phase II study of pentostatin and intermittent high?dose recombinant interferon alfa?2a in advanced mycosis fungoides/Sezary syndrome. J Clin Oncol, 10:1907?1913, 1992.

Breneman DL, Ariano M: Successful treatment of acne vulgaris in women with a new topical sodium sulfacetamide/sulfur lotion. Int J Dermatol, 32:365-367, 1993.

Doebbeling BN, Breneman DL, Neu HC, Aly R, Yangco BG, Holley HP, Marsh RJ, Pfaller MA, McGowan JA, Scully BE, Reagan DR, Wenzel RP: Elimination of Staphylococcus aureus nasal carriage in health care workers: analysis of six clinical trials with calcium mupirocin ointment. Clin Infect Dis, 17:466-474, 1993.

Breneman DL: Bath PUVA therapy for allergic contact dermatitis of the hands and feet. Clinical Cases in Dermatology, 5:13-17, 1993.

Breneman DL: Bacterial infections of the skin and soft tissues, and their treatment. Current Opinion in Infectious Diseases, 6:678-682, 1993.

Breneman DL, Breneman JC: Cutaneous T?cell lymphoma mimicking porokeratosis of Mibelli. J Am Acad Dermatol, 29:1046-1048, 1993.

Breneman DL: Treating skin infections with topical antibiotics. The Female Patient, 18:65-71, 1993.

Breneman JC, Goldschmidt H, Breneman DL: Ionizing radiation therapy in dermatology (CME article). J Am Acad Dermatol, 30:157-182, 1994.

Fivenson DP, Breneman DL, Rosen GB, Hersh CS, Cardone JS, Mutasim D: Nicotinamide and tetracycline therapy of bullous pemphigoid. Arch Dermatol, 130:753-758, 1994.

Drake LA, Fallon JD, Sober A, Breneman DL, Brown RH, Chalker D, Edwards L, Funicella T, Greene SL, Kantor I, Katz HI, Maize JC, Millikan LE, Monroe EW, Raimer SS, Schupbach CW, Smith EB: Relief of pruritus in patients with atopic dermatitis after treatment with topical doxepin cream. J Am Acad Dermatol 31:613-616, 1994.

Highton A, Quell J, Breneman D, Cullen S, Goffe B, Griffiths C, Huerter C, Kingsley D, Piacquadio D, Pincus S, Rogers R, Scher R: Calcipotriene ointment 0.005% for psoriasis: A safety and efficacy study. J Am Acad Dermatol 32:67-72, 1995.

Breneman D, Bronsky EA, Bruce S, Kalivas JT, Klein GL, Roth HL, Tharp MD, Treger C, Soter N: Cetirizine and astemizole in chronic idiopathic urticaria: A double-blind, placebo-controlled comparative trial. J Am Acad Dermatol 33:192-198, 1995.

Drake LA, Millikan LE, Breneman DL, Brown RH, Chalker D, Edwards L, Fallon JD, Funicella T, Greene SL, Kantor I, Katz HI, Maize JC, Monroe EW, Raimer SS, Schupbach CW, Smith EB, Sober A: The antipruritic effect of 5% doxepin cream in patients with eczematous dermatitis. Arch Dermatol 131:1403-1408, 1995.

Breneman DL: Cetirizine vs. hydroxyzine and placebo in chronic idiopathic urticaria: A comparison with hydroxyzine and placebo. Ann Pharmacother, 30:1075-1079, 1996.

Breneman DL: Evaluation of cutaneous lymphomas. Compr Ther, 22:169-174, 1996.

Lebwohl M, Siskin S, Epinette W, Breneman D, Funicella T, Kalb R, Moore J: A multi-center trial of calcipotriene ointment and halobetasol ointment compared to either agent alone for the treatment of psoriasis. J Am Acad Dermatol, 35:268-269, 1996.

Pariser DM, Pariser RJ, Breneman D, Lebwohl M, Kalb R, Moore J, Moss H, Parker C, Fiedler V: Calcipotriene ointment applied once a day for psoriasis: A double-blind multicenter placebo-controlled study. Arch Dermatol, 132:1527, 1996.

Wibowo AS, Hurtubise PE, Breneman DL, Stroop DM, Steele PE, Schumacher HR: Evaluation of peripheral blood in patients with mycosis fungoides/Sézary syndrome. Lab Hematol 3:3-9, 1997.

Breneman DL: Mycosis fungoides, Sézary syndrome, and the other cutaneous T-cell lymphomas: Past and present. J Ger Dermatol, 5:A11-A14, 1997.

Breneman DL, Breneman JC: Evaluation and treatment of patients with cutaneous T-cell lymphoma. J Ger Dermatol, 5:339-346, 1997.

Breneman JC, Breneman DL: Use of radiotherapy in the treatment of mycosis fungoides. J Ger Dermatol, 5:358-363, 1997.

Breneman DL, Dunlap FE, Monroe EW, Schupbach CW, Shmunes E, Phillips SB: Doxepin cream relieves eczema-associated pruritus within 15 minutes and is not accompanied by a risk of rebound upon discontinuation. J Dermatol Treat, 8:161-168, 1997.

Breneman DL: Advances in dermatologic therapy with antihistamines. Curr Opin Dermatol, 4:241-245, 1997.

Breneman D, Stewart D, Hevia O, Hino P, Drake L: A double-blind, multi-center clinical trial comparing efficacy of once daily metronidazole 1% cream to vehicle in patients with rosacea. Cutis, 61:44-47, 1998.

Ploysangam T, Breneman DL, Mutasim DF: Cutaneous pseudolymphomas. J Am Acad Dermatol, 38:877-905, 1998.

Bagel J, Garland WT, Breneman D, Holick M, Littlejohn TW, Crosby D, Faust H, Fivenson D, Nichols J: Administration of DAB₃₈₉IL-2 to patients with recalcitrant psoriasis: A double-blind, phase II multicenter trial. J Am Acad Dermatology 38:938-944, 1998.

Scher RK, Breneman D, Rich P, Savin RC, Feingold DS, Konnikov N, Shupack JL, Pinnell S, Levine N, Lowe NJ, Aly R, Odom RB, Greer DL, Morman MR, Monroe AD, Tschen EH, Elewski BE, Smith EB: A placebo-controlled, randomized, double-blind trial of once-weekly fluconazole (150 mg, 300 mg or 450 mg) in the treatment of distal subungual onychomycosis of the toenail. J Amer Acad Dermatol, 38:S77-S86, 1998.

Drake L, Babel D, Stewart DM, Rich P, Ling MR, Breneman D, Scher RK, Martin AG, Pariser DM, Pariser RJ, Ellis CN, Kang S, Katz HI, McDonald CJ, Muglia J, Savin RC, Webster G, Elewski BE, Leyden JJ, Monroe AD, Tschen EH, Hanifin JM, Morman MR, Shupack JL, Levine N, Lowe NJ, Bergfeld WF, Camisa C, Feingold DS, Konnikov N, Odom RB, Aly R, Greer DL: Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the fingernail. J Amer Acad Dermatol, 38:S87-S94, 1998.

Rich P, Scher RK, Breneman D, Savin RC, Feingold DS, Konnikov N, Shupack JL, Pinnell S, Levine N, Lowe NJ, Aly R, Odom RB, Greer DL, Morman MR, Monroe AD, Tschen EH, Elewski BE, Smith EB, Hilbert J: Pharmacokinetics of three doses of once-weekly fluconazole (150, 300, 450 mg) in distal subungual onychomycosis of the toenail. J Amer Acad Dermatol, 38:S103-S109, 1998.

Savin RC, Drake L, Babel D, Stewart DM, Rich P, Ling MR, Breneman D, Scher RK, Martin AG, Pariser DM, Pariser RJ, Ellis CN, Kang S, Friedman D, Katz HI, McDonald CJ, Muglia J, Webster G, Elewski BE, Leyden JJ, Monroe AD, Tschen EH, Hanifin JM, Morman MR, Shupack JL, Levine N, Lowe NJ, Bergfeld WF, Camisa C, Feingold DS, Konnikov N, Odom RB, Aly R, Greer DL, Hilbert J: Pharmacokinetics of three once-weekly dosages of fluconazole (150 mg, 300 mg, or 450 mg) in distal subungual onychomycosis of the fingernail. J Amer Acad Dermatol, 38:S110-S116, 1998.

Lebwohl MG, Breneman DL, Goffe BS, Grossman JR, Ling MR, Milbauer J, Pincus SH, Sibbald RG, Swinyer LJ, Weinstein GD, Lew-Kaya DA, Lue JC, Gibson JR, Sefton J: Tazarotene 0.1% gel plus corticosteroid cream in the treatment of plaque psoriasis. J Am Acad Dermatol 39:590-596, 1998.

Koo J, Cuffie CA, Tanner DJ, Bressinck R, Cornell RC, DeVillez RL, Edwards IE, Breneman DL, Piacquadio DJ, Guzzo CA, Monroe EW. Mometasone furoate 0.1%/salicylic acid 5% ointment versus mometasone furoate 0.1% ointment in the treatment of moderate to severe psoriasis: A multicenter study. Clin Ther, 20:283-291, 1998.

DeVillez RL, Sher AM, Breneman DL, Espy PD, Garcia CJ, Monroe EW, Tanner DJ, Cuffie CA: Comparison of the efficacy and safety of mometasone furoate ointment 0.1% once daily and fluticasone propionate ointment 0.005% twice daily in the management of psoriasis. Adv Ther 15:92-97, 1998.

Berberian BJ, Breneman DL, Drake LA, Gratton D, Raimir SS, Phillips S, Sulica VI, Bernstein JE. The addition of topical doxepin to corticosteroid therapy: An improved treatment regimen for atopic dermatitis. Int J Dermatol, 38:145-148, 1999.

Breneman DL, Hanifin JM, Berge CA, Keswick BH, Neumann PB: The effect of an antibacterial bar soap with 1.5% TCC on the clinical improvement and microbial skin flora in patients with atopic dermatitis. Cutis 66:296-300, 2000.

Adamick C, Breneman D: Diffuse and progressive papules and nodules. Arch Dermatol, 136:791-796, 2000.

Duvic M, Hymes K, Heald P, Breneman D, Martin AG, Myskowski P, Crowley C, Yocum RC: Bexarotene is effective and safe for treatment of refractory advanced stage cutaneous T-cell lymphoma: Multinational phase II-III trial results. J Clin Oncol, 19:2456-2471, 2001.

Duvic M, Martin A, Kim Y, Olsen E, Wood G, Crowley C, Yocum R, Aeling J, Bagot M, Mondor H, Bernard P, Debre R, Bran E, Breneman D, Burg G, Diez L, el-Azhary R, Fivenson D, Foss F, Heald P, Joly P, et al: Phase 2 and 3 clinical trial of oral bexarotene for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol, 137:581-593, 2001.

Ring J, Hein R, Gauger A, Bronsky E, Miller B, Breneman D, Conneley M, et al: Once daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: A randomized, double-blind, placebo-controlled study. Int J Dermatol 40:1-3, 2001.

Hanifin JM, Ling MR, Langley R, Breneman D, Rafal E, et al: Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: Part I, efficacy. J Am Acad Dermatol, 44:S28-S38, 2001.

Drake L, Prendergast M, Maher R, Breneman D, Cooper K, Beusterien KM, Lawrence I: The impact of tacrolimus ointment on health-related quality-of-life of adult and pediatric patients with atopic dermatitis. J Am Acad Dermatol, 44:S65-S72, 2001.

Breneman D, Duvic M, Kuzel T, Yocum R, Truglia J, Stevens W: Phase I-II trial of bexarotene gel for the skin-directed treatment of patients with cutaneous T-cell lymphoma. Arch Dermatol 138:325-332, 2002.

Kulow BF, Cualing H, Steele P, VanHorn J, Breneman JC, Mutasim DF, Breneman DL: Progression of cutaneous B-cell pseudolymphoma to cutaneous B-cell lymphoma". J Cutan Med Surg, 6:519-528, 2002.

Weinstein GD, Koo JYM, Krueger GG, Lebwohl MG, Lowe NJ, Menter A, Lew-Kaya DA, Seflon J, Gibson JR, Walker PS, Ast E, Bagel J, Breneman DL, Bright RD, Davis SA, Duvic M, Eisen D, Feldman SR, Fiedler VC, Fitzpatrick R, Fivenson DP, Goffe BS, Hanifin JM, Hong SR, Jones TM, Kempers SE, Kraus SJ, Krusinski PA, Leyden JJ, Maloney JM, Miller BH, Pariser DM, Phillips TJ, Reyes B, Reynolds O, Shauin JS, Stewart D, Swinyer LJ, Tschen EH, Wolf DI: Tazarotene cream in the treatment of psoriasis: Two multicenter double-blind randomized, vehicle-controlled studies of the safety and efficacy of tazarotene cream 0.05% and 0.1% applied once daily for 12 weeks. J Am Acad Dermatol, 48:760-767, 2003.

Breneman DL, Raju US, Breneman JC, Steele PE, Swerdlow SH, Cualing HD: Lymph node grading for staging of mycosis fungoides may benefit from examination of multiple excised lymph nodes. J Amer Acad Dermatol, 48:702-706, 2003.

Heald P, Mehlmauer M, Martin A, Crowley C, Yocum R, Reich S, Aeling J, Bran E, Breneman D, Burg G, Duvic M, elAzhary R, Fivenson D, Gaspari A, Joly P, Nicolle C, Kashani-Sabet M, Lecewicz-Tourun B, Lowe N, Millikan L, Muglia J, Olsen E, Pluzanska A, Prince H, MacCallum P, Sauder D, Turner R, Washenik K,Wood G, Zone J. Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: Results of the phase III clinical trial. J Am Acad Dermatol 49:801-815, 2003.

Hanifin J, Stevens V, Sheth P, Breneman D: Novel treatment of chronic severe hand dermatitis with bexarotene gel. Br J Dermatol, 150:545-553, 2004.

Breneman D, Savin R, VandePol C, Vamvakias G, Levy S, Leyden J: Double-blind, randomized, vehicle-controlled clinical trial of once daily benzoyl peroxide / clindamycin topical gel in the treatment of patients with moderate to severe rosacea. Int J Dermatol, 43:381-387, 2004.

Jarratt M, Breneman D , Gottlieb A, Poulin Y, Lin Y, Foley V. Clobetasol propionate shampoo: A new option to treat patients with moderate to severe scalp psoriasis. J Drugs Dermatol, 3:367-373, 2004.

Kang S, Krueger GG, Tanghetti EA, Walker PS, Gibson JR, Lew-Kaya D, Sefton J, Breneman DL, Bruce S, Falanga V, Hanke CW, Miller BH, Pariser DM, Reynolds OD, Savin RC, Shavin JS, Smith SR, Webster GF, Weinstein GD: A multicenter, randomized, double-blind trial of tazarotene 0.1% cream in the treatment of photodamage. J Am Acad Dermatol 52:268-274, 2005.

Breneman D, Fleischer A, Kaplan D, Kraus S, Lebwohl M, Miller B, Pariser D, Rist T, Swinger L, Liu Y: Clobetasol propionate lotion 0.05% in the treatment of moderate to severe atopic dermatitis: A randomized evaluation versus clobetasol propionate emollient cream. J Drugs Dermatol, 4:330-336, 2005.

Chapman MS, Schachner LA, Breneman D, Boguniewicz M, Gold MH, Schull T, Linowski GJ, Jaracz E: Tacrolimus ointment 0.03% shows efficacy and safety in pediatric and adult patients with mild to moderate atopic dermatitis. J Am Acad Dermatol, 53:S177-185, 2005.

Lorenzo CR, Swerdlow SH, Breneman D: Primary cutaneous marginal zone B-cell lymphoma with subclinical cutaneous involvement and biclonality. Submitted.

Breneman D, Sheth P, Berger V, Naini V, Stevens V: Phase II clinical trial of bexarotene gel 1% in psoriasis. Submitted.

ABSTRACTS

Breneman DL, Cardone JS, Kauffman RF, Lather RM: Topical capsaicin for treatment of pruritus related to hemodialysis. Clin Pharmacol Ther 45(2):188, 1989.

Foss F, Fischmann A, Schechter G, Ihde D, Breneman D, Breneman J, Anderson M, Eddy J, Sausville E: Phase II trial of pentostatin and interferon?alpha?2A in advanced mycosis fungoides/Sezary syndrome. Proc Amer Soc Clin Oncol 8:276, 1989.

Steele P, Breneman DL, Breneman JC, Barron D, Swerdlow SH: Genotypic Nanalysis of lymph nodes in cutaneous T cell lymphomas: Comparison with histologic "LN" grading. Lab Invest 62:95a, 1990.

Foss F, Fischmann A, Schechter G, Ihde D, Breneman D, Breneman J, Sausville E: Phase II trial of human interferon?alpha?2A and pentostatin in advanced stage mycosis fungoides/Sezary syndrome. Proc Amer Soc Clin Oncol 9:259, 1990.

Thomason JL, Gelbart SM, Scaglione JN, James JA, Breneman DL, Leong F, Broekhuizen FF: Does cefmatazole compare to cefoxitin or penicillin for treatment of gonorrhea? Proc Intersci Conf Antimicrob Agent Chemother 30:251, 1990.

Breneman DL: Topical corticosteroid therapy for severe scalp psoriasis. Clin Pharmacol Ther 51(2):128, 1992.

Breneman D, Bergstresser P, Boggs P, Bronsky E, Bruce S, Grossman J, Kalivas J, Klein G, Roth H, Sotor N, Tharp M, Treger C: A multi?site comparative study of the efficacy and safety of cetirizine vs. astemizole and placebo in the treatment of chronic idiopathic urticaria. J All Clin Immunol 89(1):249, 1992.

Drake L, Breneman D, Greene S, Raimer S, Shupbach CW, Halperin M: Effects of topical doxepin 5% cream on pruritic eczema. J Invest Dermatol 98(4): 605, 1992.

Sorensen SM, Barron DR, Breneman DL, Breneman JC, Swerdlow SH: Paraffin section immunohistologic evaluation of cutaneous T?cell lymphomas: The role of OPD4. Lab Invest 66:88A, 1992.

Breneman DL, Like?Nartker A, Ballman EA, Pruemer JM, Blumsack RF, Davis M, Breneman JC: Topical mechlorethamine in the treatment of mycosis fungoides ? uniformity of application and potential for environmental contamination. 18th World Congress of Dermatology: Progress and Perspectives 18:29A, 1992.

Breneman DL, Breneman JC, Wachendorf TJ, Rindler JM, Ballman EA: Hair and nail changes following total skin irradiation. 18th World Congress of Dermatology: Progress and Perspectives 18:29A, 1992.

Breneman DL, Breneman JC, Swerdlow SH, Ballman EA, Steele PE, Foss FM: Sezary syndrome: Long?term remission following topical corticosteroid therapy. 18th World Congress of Dermatology: Progress and Perspectives 18:29A, 1992.

Breneman DL, Cardone JS, Blumsack RF, Lather RM, Searle EA: Topical capsaicin for treatment of hemodialysis?related pruritus. 18th World Congress of Dermatology: Progress and Perspectives 18:29A, 1992.

Breneman DL, Swerdlow SH, Jacobs BS, Cline DJ, Barron DR, Ballman EA, Steele PE, Breneman JC: Concurrent lymphomatoid papulosis and mycosis fungoides. 18th World Congress of Dermatology: Progress and Perspectives 18:30A, 1992.

Breneman DL, Swerdlow SH, Breneman JC, Ballman EA, Kuhlman DS, Steele PE: Concurrent Ki?1 lymphoma, lymphomatoid papulosis, and mycosis fungoides. 18th World Congress of Dermatology: Progress and Perspectives 18:30A, 1992.

Mutasim DF, Breneman DL, Lorton C, Anhalt GJ: Paraneoplastic pemphigus: Autopsy findings. 18th World Congress of Dermatology: Progress and Perspectives 18:162A, 1992.

Rosen GB, Fivenson DP, Breneman DL, Hersch CS, Cardone JS, Mutasim D: Nicotinamide and tetracycline treatment of autoimmune bullous disorders. 18th World Congress of Dermatology: Progress and Perspectives 18:194A, 1992.

Doebbeling B, Breneman D, Marsh R, Reagan D, Wenzel R: Multi?center study of elimination of Staphylococcus aureus nasal carriage with calcium mupirocin ointment in healthy subjects. Proc Intersci Conf Antimicrob Agent Chemother 32:392, 1992.

Hebert AA, Breneman DL, Grier CE, McCree LC: Comparison of topical mupirocin ointment and oral cephalexin in the treatment of secondarily infected skin ulcers. Proc Intersci Conf Antimicrob Agent Chemother 32:392, 1992.

Breneman DL: The efficacy of cetirizine compared to terfenadine and astemizole in the treatment of chronic urticaria. Proc European Acad Dermatol Venereol 3:107, 1993.

Breneman DL, Ariano MC, Evans C, Davis MJ, Rumsfield JA, West DP: Adult female acne treatment with a new topical sodium sulfacetamide/sulfur lotion. Pharmacotherapy 13:268, 1993.

Breneman DL, Like?Nartker A, Ballman EA, Pruemer JM, Blumsack RF, Davis M, Breneman JC: Topical mechlorethamine in the treatment of mycosis fungoides ? uniformity of application and potential for environmental contamination. In The 1993 Year Book of Dermatology, AJ Sober, TB Fitzpatrick, eds. Mosby-Year Book, Inc., St. Louis, 1993, pp. 365-366.

Breneman DL, Cardone JS, Blumsack, RF, Lather RM, Searle EA: Topical capsaicin for treatment of hemodialysis-related pruritus. In The 1993 Year Book of Dermatology, AJ Sober, TB Fitzpatrick, eds. Mosby-Year Book, Inc., St. Louis, 1993, pp. 172-173.

Childress L, Utz G, Cualing H, Debowsky T, Breneman D, Breneman J,Steele P: BCL-2 oncoprotein distinguishes benign from malignant in cutaneous lymphoid lesion biopsies. Modern Pathol, 7:105A, 1994.

Wibowo A, Mikhael A, Stroop DM, Hill J, Reisinger J, Breneman D, Hurtubise P, Steele P, Yochman L, Schumacher HR: Sézary cell expression in mycosis fungoides. Blood 84:598A, 1994.

Pincus S, Oseroff A, Breneman D, Foss F, Koh H, Duvic M, Vonderheid EC, Coe B, Phillips SB, Bernstein JE: Effectiveness of topical naloxone, an opioid antagonist, in the treatment of pruritus associated with mycosis fungoides and Sézary syndrome. J Invest Dermatol 104:661, 1995.

Berberian BJ, Sulica VI, Breneman DL, Drake LA, Gratton D, Raimer SS, Bernstein JE, Halperin M: Effects of adding topical doxepin to topical corticosteroid therapy in atopic dermatitis. J Invest Dermatol 104:691, 1995.

Breneman D, Bronsky EA, Bruce S, Valivas JT, Klein GL, Roth HL, Thorp MD, Treger C, Soter N: Cetirizine and astemizole in chronic idiopathic urticaria: A double-blind, placebo-controlled comparative trial. In The 1996 Year Book of Dermatology, AJ Sober, TB Fitzpatrick, eds. Mosby-Year Book, Inc., St. Louis, 1996, pp. 459-461.

Breneman DL, Duvic M, Kuzel T, Stevens V, Yocum R: Phase 1-2 clinical trial supports the safety and efficacy of Targretin topical gel, a novel RXR-selective retinoid analogue, in the treatment of cutaneous T-cell lymphoma. J Amer Soc Hematol 88:569a, 1996.

Duvic M, Breneman D, Kuzel T, Straus D, Stevens V, Yocum R. LGD1069, a novel RXR-selective retinoid analogue in the treatment of cutaneous T-cell lymphoma. Proceedings of the International Society of Cutaneous Lymphomas; Sydney, Australia, 1997.

Kuzel T, Breneman D, Duvic M, Truglia J, Yocum R, Stevens V: Phase I-II trial of targretin gel in the topical treatment of patients with CTCL. J Invest Dermatol 114:839, 2000.

Bridges AG, Breneman DL, Mutasim DF, Gibson LE: Primary cutaneous natural killer cell lymphoma compared to natural killer-like T-cell lymphoma presenting with massive cutaneous involvement.

J Cutaneous Pathol 27:550, 2000.

Breneman D, Sheth P, Stevens V, Hanifin J: Bexarotene, a rexinoid, is anti-inflammatory in severe hand dermatitis. Inflammation Research 52(2):S108, 2003.

Sheth P, Breneman D, Stevens V, Hanifin J: Severe hand dermatitis is responsive to topical bexarotene 1% gel. J Invest Dermatol 120:A0356, 2003.

Chapman MS, Schachner L, Breneman D, Boguniewicz M: Tacrolimus ointment 0.03% is safe and effective for the treatment of mild to moderate atopic dermatitis. J Am Acad Dermatol 50:P3(P11), 2004.

Breneman DL, Sheth P, Stevens V: Pilot trial of topical bexarotene gel in mild to moderate plaque psoriasis. J Am Acad Dermatol 50:P152(P593), 2004.

Breneman D, Fleischer AB, Antaya R, Langley RG: Tacrolimus ointment vs. pimecrolimus cream in patients with moderate atopic dermatitis. J Am Acad Dermatol 52:P73,2005.

Duvic M, Breneman D, Cooper M, Fonseca G, Bennett JC, Kilpatrick JM, Bantia S: Phase I/II study of oral forodesine, a PNP inhibitor in refractory cutaneous T-cell lymphoma patients. Blood, 106:2683, 2005.

Breneman D, Fleischer A, Abramovits W, Farber H: Tacrolimus ointment with and without topical steroids in patients with moderate to severe atopic dermatitis. J Am Acad Dermatol 54:AB88, 2006.

LETTERS TO EDITOR

Breneman DL, Breneman JC: Topical mechlorethamine in the treatment of mycosis fungoides. J Am Acad Dermatol, 27(5):786?787, 1992.

Breneman J, Breneman D: Total skin irradiation for mycosis fungoides associated with lymphomatoid papulosis. Int J Rad Oncol, Biol, Phys 32:274, 1995.

Breneman DL, Steele PE, Cualing HD, Breneman JC, Nussbaum MS, Swerdlow SH. Should multiple lymph nodes be taken? J Am Acad Dermatol, 51(3):483-484,2004.

CHAPTERS

Nordlund JJ, Breneman DL, Pelc NJ, King AD: Melanoma, Kaposi's sarcoma, and mycosis fungoides. In Stein's Internal Medicine, fourth edition, JH Stein, JJ Hutton, et al, eds. Mosby-Year Book, Inc., St. Louis, 1993, pp. 919-924.

Breneman DL: Advances in dermatologic therapy with antihistamines. In Current Opinion in Dermatology, volume 4, MV Dahl, ed. Rapid Science Publishers, Philadelphia, Pennsylvania, 1997, pp 241-245.

Breneman DL: Cutaneous T-cell lymphoma. In The Pigmentary System and Its Disorders, JJ Nordlund, RE Boissy, VJ Hearing, RA King, JP Ortonne, eds. Oxford University Press, New York, New York, 1998, pp 878-883.

Breneman DL, VanHorn JA, Breneman JC: Costs of evaluating and treating patients with cutaneous T-cell lymphoma. In Care Management of Skin Diseases: Life Quality and Economic Impact, R Rajagopalan, EF Sherertz, RT Anderson, eds. Marcel Dekker Inc., New York, New York, 1998, pp 355-367.

GUEST EDITOR

Journal of Geriatric Dermatology: Special issue on cutaneous T-cell lymphoma. Volume 5, 1997.

PARTICIPATION IN PROFESSIONAL MEETINGS

Presentations at International Meetings

Breneman DL, Breneman JC, Wachendorf TJ, Rindler JM, Ballman EA: Hair and nail changes following total skin irradiation. 18th World Congress of Dermatology, New York, New York 6/15/92.

Breneman DL, Cardone JS, Blumsack RF, Lather RM, Searle EA: Topical capsaicin for treatment of hemodialysis?related pruritus. 18th World Congress of Dermatology, New York, New York 6/15/92.

Kalivas J, Breneman D, Bergstresser P, Boggs P, Bronksy E, Bruce S, Grossman J, Klein G, Roth H, Tharp M, Treger C, deMahieu C: A multi?site comparative study of the efficacy and safety of cetirizine vs. astemizole and placebo in the treatment of chronic idiopathic urticaria. First Asian Pacific Congress of Allergology and Immunology, Bangkok, Thailand 11/23/92.

Breneman DL: The efficacy of cetirizine as compared to terfenadine and astemizole in the treatment of chronic urticaria. Third Congress of the European Academy of Dermatology and Venereology, Copenhagen, Denmark 9/28/93.

Breneman DL: Cutaneous T-cell lymphomas other than mycosis fungoides. Second International Symposium on Cutaneous T-Cell Lymphomas, Chicago, Illinois 10/16/93.

Breneman DL: Cost issues in the treatment of cutaneous T-cell lymphoma. International Consensus Conference on Staging and Treatment Recommendations for Cutaneous T-Cell Lymphoma, Cambridge, Massachusetts 10/1/94.

Breneman DL: Newer therapeutic modalities for acne. Symposium on the Use of Tazarotene in Dermatology, Niagra on the Lake, Canada 5/3/97.

Breneman DL, Berge CA, Keswick BH, Neumann PB: Evaluation of the effect of an antibacterial bar soap with 1.5% TCC on the clinical improvement and microbial skin flora in patients with atopic dermatitis. Venezuelan Dermatology Congress / First Venezuelan-Columbian Dermatology Congress, Caracas, Venezuela 11/12/97.

Breneman D, Berge C, Keswick B, Neumann P, Volkovynsky K: Evaluation of the effect of an antibacterial soap with 1.5% triclocarbon on the clinical improvement and microbial skin flora in patients with atopic dermatitis. Ukranian Congress of Dermatologists, Ukraine, 9/9/99.

Bilheimer W, Breneman D, Berge C, Keswick B, Neumann P: Evaluation of the effect of an antibacterial soap with 1.5% triclocarbon on the clinical improvement and microbial skin flora in children with atopic dermatitis. World Health Organization Health and Hygiene Symposium, Beijing, China, 7/22/02

Presentations at International Meetings – Discussion Sessions

Blanco R, Miller MA, Bridges A, Steele P, Breneman D, Zaknoen S: Peripheral T-cell lymphoma. European Association for Haematopathology IX meeting, Leiden, The Netherlands, 4/27/98.

Duvic M, Breneman D, Kuzel T, Straus D, Stevens V, Yocum R: LGD1069, a novel RXR selective retinoid analogue in the treatment of cutaneous T-cell lymphoma. European Society for Dermatologic Research in Cutaneous Lymphomas, Berlin, Germany, 9/28/98.

International Exhibits

Childress L, Utz G, Cualing H, Debowsky T, Breneman D, Breneman J, Steele P: BCL-2 oncoprotein distinguishes benign from malignant in cutaneous lymphoid lesion biopsies. International Academy of Pathologists 1994 annual meeting, San Francisco, California 3/13-14/94.

Duvic M, Breneman D, Kuzel T, Straus D, Stevens V, Yocum R: LGD1069, a novel RXR-selective retinoid analogue, in the treatment of cutaneous T-cell lymphoma. International Society for Cutaneous Lymphomas, Sydney, Australia 6/14/97.

Cualing H, Penmetsa U, Steele P, Nussbaum M, Breneman D: LN grading for staging of mycosis fungoides may benefit from examination of multiple excised lymph nodes. Pan-Pacific Lymphoma Conference, Lanai, Hawaii 7/15-18/97

Breneman D, Vaishnaw A, Lee S, Shrager D: Repeat courses of alefacept for the treatment of chronic plaque psoriasis demonstrate effects similar to those of a single course. Canadian Dermatological Association 76th annual conference, Halifax, Nova Scotia, 6/28-30/01.

Breneman D, Fleischer A, Kaplan D, Kraus S, Lebwohl M, Miller B, Pariser D, Rist T, Swinger , Liu Y, Foley V: Clobetasol propionate lotion, 0.05% in the treatment of moderate to severe atopic dermatitis: An efficient and safe alternative to clobetasol propionate emollient cream. 20^th World Congress of Dermatology, Paris, France, 7/1-5/02.

Jarratt M, Breneman D, Gottlieb A, Poulin Y, Liu Y, Foley V. Clobetasol propionate shampoo: A new option for moderate to severe scalp psoriasis. 11^th Congress of the European Academy of Dermatology and Venereology, Prague, Czech Republic, 10/3-7/02.

Breneman D, Sheth P, Stevens V, Hanifin J. Bexarotene, a rexinoid, is anti-inflammatory in severe hand dermatitis. 6^th World Congress on Inflammation, Vancouver, Canada, 8/2-8/03.

Lorenzo CR, Swerdlow S, Breneman D: Primary cutaneous immunocytoma/marginal zone B-cell lymphoma with diffuse subclinical involvement demonstrating kappa and lambda light chain restrictions. International Symposium on the Biology and Immunology of Cutaneous Lymphoma, Berlin, Germany, 2/3-5/05.

Presentations at National Meetings

Breneman DL: Secondary skin infections and topical therapy considerations. Focus on Dermatological Infections: Clinical Advances ? A National Symposium; sponsored by University of Pennsylvania School of Medicine, Williamsburg, Virginia 3/13/88.

Breneman DL: A randomized, double?blind, vehicle?controlled evaluation of mupirocin for the treatment of secondarily infected dermatoses. American Academy of Dermatology 1988 summer session, New York, New York 6/16/88.

Breneman DL, Kauffman RF, Cardone JS, Lather RM: Topical capsaicin for treatment of pruritus related to hemodialysis. American Society for Clinical Pharmacology and Therapeutics annual meeting, Nashville, Tennessee 3/10/89.

Breneman DL: Bath PUVA: Practical use for a variety of dermatoses. American Academy of Dermatology 1989 annual meeting, San Francisco, California 12/5/89.

Steele P, Breneman DL, Breneman JC, Barron DR, Swerdlow SH: Genotypic analysis of lymph nodes in cutaneous T cell lymphomas: Comparison with histologic "LN" grading. United States and Canadian Academy of Pathology annual meeting, Boston, Massachusetts 3/5/90.

Cardone JS, Breneman DL: Topical capsaicin for the treatment of hemodialysis?related pruritus. American Academy of Dermatology 1990 annual meeting, Atlanta, Georgia 12/3/90.

Fivenson DP, Breneman DL, Cardone JS, Hersh C, Rosen G, Mutasim DF: Nicotinamide and tetracycline therapy of auto?immune bullous disorders. American Academy of Dermatology 1991 summer session, Monterey, California, 6/13/91.

Breneman DL: Bath PUVA: Practical use for a variety of dermatoses. American Academy of Dermatology 1991 annual meeting, Dallas, Texas 12/10/91.

Breneman DL, Bergstresser P, Boggs P, Bronksy E, Bruce S, Grossman J, Kalivas J, Klein G, Roth H, Tharp M, Treger C: A Multi?site comparative study of the efficacy and safety of cetirizine vs. astemizole and placebo in the treatment of chronic idiopathic urticaria. American Academy of Allergy and Immunology 48th annual meeting, Orlando, Florida 3/9/92.

Breneman DL: Cutaneous lymphomas ? evaluation and staging. American Academy of Dermatology 1993 summer session, Toronto, Canada 7/16/93.

Breneman DL: Cutaneous lymphomas - evaluation and staging. American Academy of Dermatology 1993 annual meeting, Washington, D.C. 12/8/93.

Breneman DL: Therapeutic challenge: Cutaneous T-cell lymphoma. American Academy of Dermatology 1993 annual meeting, Washington, D.C. 12/9/93.

Breneman DL: Help, help, I'm itching and I can't stop! American College of Allergy, Asthma, and Immunology annual meeting, Dallas, Texas 11/12/95.

Breneman DL: Evaluation of cutaneous lymphomas. American Academy of Dermatology 1996 annual meeting, Washington, D.C. 2/13/96.

Breneman DL: Topical anti-pruritic update. American Academy of Dermatology 1996 annual meeting, Washington, D.C. 2/14/96.

Breneman DL: Chronic urticaria: How can you make a difference in your patient's condition? American Academy of Physician Assistants annual meeting. New York, New York 5/28/96.

Breneman DL: Clinical treatment applications of tazarotene: acne vs. psoriasis. Tazarotene Clinical Update meeting, New York, New York 9/28/96.

Breneman DL: Evaluation of cutaneous lymphomas. American Academy of Dermatology annual meeting, San Francisco, California 3/21/97.

Maibach H, Breneman D, Tschen E, Reyes J, Jones T, DeVillez R: Butenafine HCl 1% / betamethasone dipropionate 0.05% cream in the one-week treatment of tinea pedis. Skin Disease Education Foundation annual meeting, Santa Fe, New Mexico 10/16/97.)

Breneman DL: Cutaneous T-cell lymphomas: Patient support groups and the internet. American Academy of Dermatology annual meeting, Orlando, Florida 2/28/98.

Breneman DL: Evaluation of cutaneous lymphomas. American Academy of Dermatology annual meeting, Orlando, Florida 2/28/98.

Breneman DL: American Academy of Dermatology recertification course: Update on cutaneous T-cell lymphoma. American Academy of Dermatology annual meeting, New Orleans, Louisiana 3/20/99.

Breneman DL: Cutaneous T-cell lymphomas: Patient support groups and the internet. American Academy of Dermatology annual meeting, New Orleans, Louisiana 3/20/99.

Breneman DL: Evaluation of cutaneous lymphomas. American Academy of Dermatology annual meeting, New Orleans, Louisiana 3/20/99.

Bridges AG, Breneman DL, Mutasim DF, Gibson LE: Primary cutaneous natural killer cell lymphoma compared to natural killer-like T-cell lymphoma presenting with massive cutaneous involvement. American Society of Dermatopathology 37th annual meeting, Baltimore, Maryland 10/21/00.

Lorenzo C, Swerdlow S, Breneman D: Cutaneous immunocytoma/marginal zone B-cell lymphoma presenting with diffuse subclinical involvement and demonstrating kappa and lambda light chain restriction. American Society of Dermatopathology 31^st national meeting, Boston, Massachusetts 10/14/04.

Presentations at National Meetings ? Gross and Microscopic Symposia

Breneman DL, Estes SA: Perforating folliculitis associated with vitamin A deficiency secondary to gastrointestinal malabsorption. American Academy of Dermatology 1984 annual meeting, Chicago, Illinois 12/84.

Orme RL, Breneman DL: Coexistent variegate porphyria and porphyria cutanea tarda. American Academy of Dermatology 1987 annual meeting, San Antonio, Texas 12/5/87.

Fivenson DP, Breneman DL: Systemic lupus erythematosus and pulmonary sarcoidosis. American Academy of Dermatology 1987 annual meeting, San Antonio, Texas 12/6/87.

Fu JL, Cline DJ, Breneman DL: Panniculitis associated with alpha₁?antitrypsin deficiency. American Academy of Dermatology 1988 annual meeting, Washington, D.C. 12/4/88.

Supapannachart N, Breneman DL: First isolation of human immunodeficiency virus in cutaneous blister fluid. American Academy of Dermatology 1991 annual meeting, Dallas, Texas 12/7/91.

Sheth P, Breneman D, Swerdlow S, Croen K, Mutasim D, Steele P, Whittington C, Ballman E: Granuloma formation in two patients with adult T?cell leukemia/lymphoma in sites of previous herpes zoster. American Academy of Dermatology 1992 annual meeting, San Francisco, California 12/6/92.

Hill S, Rosner S, Breneman D: Mycosis fungoides masquerading as pigmented purpuric dermatosis. American Academy of Dermatology 1996 annual meeting 2/10/96.

Lamerson C, Gloster H, Hoppenjans W, Mutasim D, Breneman D: Subcutaneous T-cell lymphoma with associated hemophagocytic syndrome mimicking pyoderma gangrenosum. American Academy of Dermatology 1997 annual meeting, San Francisco, California 3/22/97.

Bridges AG, Neltner S, Breneman D: Explosive peripheral T-cell lymphoma in a teenager. American Academy of Dermatology 1997 annual meeting, San Francisco, California 3/22/97.

Adamick C, Breneman D: Fulminant acute myelogenous leukemia presenting in the skin. American Academy of Dermatology annual meeting, New Orleans, Louisiana 3/20/99.

Fein H, Breneman DL, Mutasim DF: Pseudolymphoma mimicking mycosis fungoides secondary to contact with automatic transmission fluid. American Academy of Dermatology annual meeting, New Orleans, Louisiana 2/22/2002.

Presentations at National Meetings ? Discussion Sessions

Breneman DL, Hakim MD: Comparative cost analysis of PUVA and methotrexate in the treatment of psoriasis. American Academy of Dermatology annual meeting, Orlando, Florida 2/28/98.

Breneman DL, Storer T, Breneman JC, Mutasim DF: Methotrexate-induced cutaneous ulceration in patients with mycosis fungoides. American Academy of Dermatology annual meeting, Orlando, Florida 3/1/98.

Breneman DL, Raju US, Breneman JC, Steele PE, Swerdlow SH, Cualing HD: LN grading for staging of mycosis fungoides may benefit from examination of multiple excised lymph nodes. American Academy of Dermatology annual meeting, Orlando, Florida 3/1/98.

Breneman D, Stewart D, Hevia E, Hino P, Drake L: A clinical efficacy trial of 1% metronidazole cream administered once daily in the treatment of rosacea. American Academy of Dermatology annual meeting, Orlando, Florida 3/3/98.

Breneman DL, VanHorn JA, Breneman JC: Cutaneous T-cell lymphoma and patient support groups. American Academy of Dermatology annual meeting, New Orleans, Louisiana 3/21/99.

National Exhibits

Kalivas JT, Breneman DL, Tharp M: Cetirizine, a novel antihistamine for the treatment of chronic idiopathic urticaria. American Academy of Dermatology 1988 annual meeting, Washington, D.C. 12/4?7/88. Bronze award for original scientific investigation.

Foss F, Fischmann A, Schechter G, Ihde D, Breneman D, Breneman J, Sausville E: Phase II trial of human interferon?alfa?2A and pentostatin in advanced stage mycosis fungoides/Sezary syndrome. American Society for Clinical Oncology 1990 annual meeting, Washington, D.C. 5/20?22/90.

Thomason JL, Gelbart SM, Scaglione JN, James JA, Breneman DL, Leong F, Broekhuizen FF: Does cefmetazole compare to cefoxitin or penicillin for treatment of gonorrhea? Results of the multicenter study. Interscience Conference on Antimicrobial Agents and Chemotherapy, Atlanta, Georgia 10/21?24/90.

Breneman DL, Dromgoole SH, Foote P, Griffith RF, Herbert AA, Hickman JG, Maloney JM, Millikan LE, Reeves LL, Sefton J, Smith EB, Sulica VI: Naftifine cream compared with clotrimazole/betamethasone dipropionate cream in the treatment of tinea pedis. American Academy of Dermatology 1990 annual meeting, Atlanta, Georgia 12/2?5/90.

Breneman DL: Topical corticosteroid therapy for severe scalp psoriasis. American Society for Clinical Pharmacology and Therapeutics annual meeting, Orlando, Florida 3/18/92.

Sorenson SM, Barron DR, Breneman DL, Breneman JC, Swerdlow SH: Paraffin section immunohistologic evaluation of cutaneous T?cell lymphomas: The role of OPD4. United States and Canadian Academy of Pathology annual meeting, Atlanta, Georgia 3/17/92.

Drake L, Breneman D, Greene S, Raimer S, Shupbach, CW, Halperin M: Effects of topical doxepin 5% cream on pruritic eczema. Society for Investigative Dermatology 1992 annual meeting, Baltimore, Maryland 4/30/92.

Doebbeling B, Breneman D, Marsh R, Reagan D, Wenzel R: Multi?center study of elimination of Staphylococcus aureus nasal carriage with calcium mupirocin ointment in healthy subjects. Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, California 10/14/92.

Hebert AA, Breneman DL, Grier CE, McCree LC: Comparison of topical mupirocin ointment and oral cephalexin in the treatment of secondarily infected skin ulcers. Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, California 10/14/92.

Breneman DL, Cooper CH, Swerdlow SH, Steele PE, Ballman EA, Cline DJ, Breneman JC: Concurrent lymphomatoid papulosis and mycosis fungoides. American Academy of Dermatology 1992 annual meeting, San Francisco, California 12/5?9/92.

Breneman DL, Ariano MC, Evans C, Davis MJ, Rumsfield JA, West DP: Adult female acne treatment with a new topical sodium sulfacetamide/sulfur lotion. American College of Clinical Pharmacy 1993 annual meeting, Reno, Nevada 8/15-18/93.

Breneman DL, Chetty VB: A multi-site comparative study of the efficacy and safety of cetirizine vs. astemizole and placebo in the treatment of chronic idiopathic urticaria. 98th Annual Convention and Scientific Seminar of the American Osteopathic Association, Boston, Massachusetts 10/10-13/93.

Tyring S, Nahlik J, Cunningham A, Marley J, Heng M, Rea T, Breneman D, et al: Efficacy and safety of famciclovir in the treatment of patients with herpes zoster: Results of the first placebo-controlled study. Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, Louisiana 10/17-20/93.

Breneman D, Breneman J, Dillow J, Swerdlow S, Ballman E, VanHorn J, Steele P, Cualing H, Mutasim D, Barron D: Primary cutaneous CD30-positive large cell lymphoma. American Academy of Dermatology 1993 annual meeting, Washington, D.C. 12/4-8/93.

Drake L, Breneman D, Monroe E, Schupach C, Halperin M: Topical doxepin hydrochloride provides an increased clinical benefit when added to topical corticosteroid treatment for atopic dermatitis. American Academy of Dermatology 1993 annual meeting, Washington, D.C. 12/4-8/93.

Breneman DL, Bronsky EA, Bruce S, Kalivas JT, Klein GL, Roth HL, Tharp MD, Treger C, Soter N: Cetirizine and astemizole in chronic idiopathic urticaria: A double-blind placebo-controlled comparative trial. American Academy of Dermatology 1995 annual meeting, New Orleans, Louisiana 2/4-8/95.

Breneman DL, Montsinger MA, VanHorn JA, Cohen RM, Breneman JC: Transient gynecomastia as an adverse effect of total skin electron beam irradiation for the treatment of cutaneous T-cell lymphoma. American Academy of Dermatology 1995 annual meeting, New Orleans, Louisiana 2/4-8/95.

Pincus S, Oseroff A, Breneman D, Foss F, Koh H, Duvic M, Vonderheid E, Coe B, Phillips S, Bernstein J: Effectiveness of topical naloxone HCl, 0.5%, in the treatment of pruritus associated with mycosis fungoides and Sézary syndrome. Society for Investigative Dermatology 1995 annual meeting, Chicago, Illinois 5/26/95.

Berberian J, Breneman DL, Hanifin JM, Drake LA, Gratton D, Raimer SS, Bernstein JE, Halperin M: Effects of adding topical doxepin to topical corticosteroid therapy in atopic dermatitis. Society for Investigative Dermatology 1995 annual meetring, Chicago, Illinois 5/26/95.

Pincus S, Oseroff A, Breneman D, Foss F, Koh H, Duvic M, Vonderheid E, Coe B, Phillips S, Bernstein J: Effectiveness of topical naloxone HCl, 0.5%, in the treatment of pruritus associated with mycosis fungoides and Sézary syndrome. American Academy of Dermatology 1995 summer meeting, Chicago, Illinois 7/22-29/95.

Breneman D, Duvic M, Kuzel T, Stevens V: Positive interim results in cutaneous T-cell lymphoma. 14th Annual Hambrecht and Quist Life Sciences Conference, San Francisco, California 1/8/96.

Sheth P, Breneman D: Allergic contact dermatitis and stomatitis to nickel-containing dental alloys. American Academy of Dermatology annual meeting, Washington, D.C. 2/10-14/96.

Breneman D, VanHorn J, Breneman J: Cutaneous T-cell lymphoma: How much does it cost. American Academy of Dermatology annual meeting, Washington, D.C. 2/10-14/96.

Breneman DL, Berge CA, Keswick BH, Neumann PB: Evaluation of the effect of an antibacterial bar soap on the clinical improvement, microbial skin flora and the use of topical steroids in patients with atopic dermatitis. The Healthcare Continuum Model on Topical Antimicrobial Wash Products in Healthcare Settings, the Food Industry, and the Home, Washington, D.C. 6/2-3/97.

Scher RK, Breneman D, Rich P, Savin R, Feingold DS, Konnikov N: Pharmacokinetics and efficacy of once-weekly fluconazole (150, 300, or 450 mg) in distal subungual onychomycosis of the toenail. American Academy of Dermatology 1998 annual meeting, Orlando, Florida 2/27-3/3/98.

Breneman DL, Berge CA, Keswick BH, Neumann PB: Evaluation of the effect of an antibacterial bar soap with 1.5% TCC on the clinical improvement and microbial skin flora in patients with atopic dermatitis. American Academy of Dermatology annual meeting, Orlando, Florida 2/27-3/3/98.

Koo J, Cuffie CA, Tanner DJ, Bressinck R, Cornell RC, DeVillez RL, Edwards L, Breneman DL, Piacquadio DJ, Guzzo CA, Monroe EW: Mometasone furoate 0.1%/salicylic acid 5% ointment twice daily versus mometasone furoate 0.1% twice daily in the management of psoriasis. American Academy of Dermatology annual meeting, Orlando, Florida 2/27-3/3/98.

Breneman DL, Storer T, Breneman JC, Mutasim DF: Methotrexate-induced cutaneous ulceration in patients with mycosis fungoides. American Academy of Dermatology annual meeting, Orlando, Florida 2/27-3/3/98.

Breneman DL, Hakim MD: Comparative cost analysis of PUVA and methotrexate in the treatment of psoriasis. American Academy of Dermatology annual meeting, Orlando, Florida 2/27-3/3/98.

Breneman D, Bucko A, Friedman D, Maloney M, Rafal E, Kang S, Tuley M, Dupre S, Plott T: Evaluation of topical metronidazole lotion in rosacea. American Academy of Dermatology annual meeting, Orlando, Florida 2/27-3/3/98.

Breneman D, Stewart D, Hevia O, Hino P, Drake L: A clinical efficacy trial of 1% metronidazole cream administered once daily in the treatment of rosacea. American Academy of Dermatology annual meeting, Orlando, Florida 2/27-3/3/98.

Breneman DL, VanHorn JA, Breneman JC: Cutaneous T-cell lymphoma patient support groups. American Academy of Dermatology annual meeting, New Orleans, Louisiana, 3/19-23/99.

Breneman L, Duvic M, Kuzel T, Stevens V, Yocum R: Phase 1-2 clinical trial demonstrates the safety and efficacy of bexarotene (LGD 1069) topical gel for the treatment of cutaneous T-cell lymphoma. American Academy of Dermatology annual meeting, New Orleans, Louisiana 3/19-23/99.

Hymes K, Duvic M, Heald P, Breneman D, Martin A, Myskowski P, Stevens V, Yocum R: Oral bexarotene benefits patients with refractory advanced stage CTCL. American Society for Hematology annual meeting, New Orleans, Louisiana 12/3-4/99.

Drake L, Prendergast M, Maher RM, Breneman D, Cooper K, Beausterien KM, Lawrence I. The health-related quality-of-life impact of tracrolimus ointment for the treatment of atopic dermatitis. American Academy of Dermatology annual meeting, San Francisco, California 3/10-14/2000.

Duvic M, Hymes K, Heald P, Breneman D, Matin A, Myskowski P: Phase II-III clinical trial in patients with refractory advanced stage CTCL demonstrates efficacy and safety of bexarotene capsules. American Academy of Dermatology annual meeting, San Francisco, California 3/10-14/2000.

Breneman D, Kulow B, Cualing H, Steele P, Breneman J, Mutasim D: Progression of cutaneous B-cell pseudolymphoma to cutaneous B-cell lymphoma. American Academy of Dermatology annual meeting, San Francisco, California 3/10-14/2000.

Kuzel T. Breneman D, Duvic M, Truglia J, Yocum R, Stevens V: Phase I-II trial of bexarotene gel in the topical treatment of patients with cutaneous T-Cell lymphoma. Society for Investigative Dermatology annual meeting, Chicago, Illinois 5/10-14/2000.

Ring J, Raimer S, Breneman D, Rikken G: Rapid onset and durability of response of destoratadine in the treatment of chronic idiopathic urticaria. American Academy of Dermatology annual meeting, Washington D.C. 3/2-6/2000.

Breneman D, Logan J, Yoichi S, Lawrence I: Comparison of racial variability in response to tacrolimus ointment for the treatment of atopic dermatitis. American Academy of Dermatology annual meeting, Washington DC 3/2-6/2001.

Breneman D, Duvic M, Kuzel T, Stevens V, Carlson A, Yocum R: Efficacy and safety of bexarotene gel in patients with previously untreated CTCL. American Academy of Dermatology annual meeting, Washington DC 3/2-6/2001.

Breneman D, Shrager D: Results of repeated course therapy with alefacept for chronic plaque psoriasis. American Academy of Dermatology summer meeting, Anaheim, California 7/28-8/1/2001.

Breneman D, Duvic M, Martin A, Yocum R: Long-term treatment of patients with early stage cutaneous T-cell lymphoma with bexarotene gel 1%. American Academy of Dermatology annual meeting, New Orleans, Louisiana 2/23-26/2002.

Breneman D, Sheth P, Stevens V, Hanifin J: Severe hand dermatitis is responsive to topical bexarotene 1% gel. Society for Investigative Dermatology annual meeting, 2003.

Jarratt M, Breneman D, Gottlieb A, Poulin Y. Clobetasol propionate shampoo: A new option for moderate to severe scalp psoriasis. American Academy of Dermatology annual meeting, San Francisco, California, 3/22-25/2003.

Hanifin J, Sheth P, Stevens V, Breneman D: Topical bexarotene gel, an RXR-selective ligand, improves chronic severe hand eczema. American Academy of Dermatology annual meeting, San Francisco, California 3/22-25/2003.

Breneman D, Leyden J: Double-blind, multicenter, comparison study of combination benzoyl peroxide/clindamycin or placebo in patients with moderate rosacea. American Academy of Dermatology annual meeting, San Francisco, California 3/22-25/2003.

Breneman D, Fleischer A, Kaplan D, Kraus S, Lebwohl M, Miller B, Pariser D, Rist T, Swinger L, Liu Y, Foley V: Clobetasol propionate lotion, 0.05% in the treatment of moderate to severe atopic dermatitis: An efficient and safe alternative to clobetasol and propionate emollient cream. American Academy of Dermatology annual meeting, San Francisco, California, 3/22-25/2003.

Chapman MS, Schachner L, Breneman D, Boguniewicz M: Tacrolimus ointment 0.03% is safe and effective in the treatment of mild to moderate atopic dermatitis in pediatric and adult patients. American Academy of Dermatology annual meeting, Washington DC, 2/6-11/2004.

Breneman DL, Sheth P, Stevens V: Pilot trial of topical bexarotene gel in mild to moderate plaque psoriasis. American Academy of Dermatology annual meeting, Washington DC, 2/6-11/2004.

Breneman D, Fleischer AB, Antaya R, Langley RG: Tacrolimus ointment versus pimecrolimus cream in patients with moderate atopic dermatitis. American Academy of Dermatology annual meeting, New Orleans, Louisiana 2/18-21/05.

Duvic M, Breneman D, Cooper M, Fonseca G, Bennett JC, Kilpatrick JM, Bantia S: Phase I/II study of oral forodesine hydrochloride, a PNP inhibitor in refractory cutaneous T-cell lymphoma patients. American Society of Hematology 47^th annual meeting, Atlanta, Georgia 12/10-13, 2005.

Breneman D, Fleischer A, Abramovits W, Farber H: Tacrolimus ointment with and without topical steroids in patients with moderate to severe atopic dermatitis. American Academy of Dermatology annual meeting, San Francisco, California 3/3-7/06

Presentations at Regional Meetings

Breneman DL: Skin and soft tissue infections. Houston Symposium Focus on Infection: 1988; sponsored by the University of Texas and M.D. Anderson Hospital and Tumor Institute, Houston, Texas 2/11/88.

Breneman DL: Skin and soft tissue infections. Dallas Symposium Focus on Infection: 1988; sponsored by the University of Texas and M.D. Anderson Hospital and Tumor Institute, Dallas, Texas 2/12/88.

Breneman DL: A randomized, double?blind study of Zostrix cream (0.025% capsaicin) and Zostrix vehicle control in the treatment of moderate to severe pruritus in patients undergoing chronic hemodialysis. Ohio Dermatological Association 1988 annual meeting, Cincinnati, Ohio 9/17/88.

Breneman DL: Mycosis fungoides. Ohio Dermatological Nurses Association 1988 annual meeting, Cincinnati, Ohio 9/17/88.

Breneman DL: Mycosis fungoides ? aggressive versus conservative therapeutic approaches. Ohio Dermatological Association 1988 annual meeting, Cincinnati, Ohio 9/18/88.

Kauffman RF, Breneman DL: Got an itch? Ohio Dermatological Nurses Association 1989 annual meeting, Columbus, Ohio 9/23/89.

Ballman EA, Breneman DL: Bath PUVA ? what, when, and how? Ohio Dermatological Nurses Association 1989 annual meeting, Columbus, Ohio 9/23/89.

Breneman DL: Mycosis fungoides ? the clinical picture. Richard W. Vilter Cancer Symposium, Cincinnati, Ohio 4/5/90.

Ballman EA, Breneman DL: Mycosis fungoides. Southwestern Tumor Registrar's Association, Cincinnati, Ohio 1/16/91.

Breneman DL: Mycosis fungoides ? diagnosis, evaluation, and management. Ohio Dermatological Nurses Association 1991 annual meeting, Dayton, Ohio, 9/14/91.

Breneman DL: Mycosis fungoides ? the clinical picture. Ohio Dermatological Association 1991 annual meeting, Dayton, Ohio 9/15/91.

Cardone JC, Breneman DL, Mutasim DF, Fivenson DF: A randomized, open label trial comparing the efficacy and safety of the combination of tetracycline and nicotinamide in the treatment of bullous pemphigoid. Ohio Dermatological Association 1991 annual meeting, Dayton, Ohio 9/15/91.

Breneman DL: Photoaging and photocarcinogenesis. Advances in Family Medicine Review Course, Cincinnati, Ohio 5/7/93.

Breneman DL: Cutaneous lymphomas. University of Louisville Department of Dermatology, Louisville, Kentucky 3/28/94.

Breneman DL: Cutaneous T-cell lymphomas other than mycosis fungoides. Ohio Dermatological Association 1994 annual meeting, Columbus, Ohio 9/17/94.

Breneman DL: Cutaneous T-cell lymphoma update. Columbus Dermatology Group, Columbus, Ohio 3/23/2000.

Breneman DL: Cutaneous T-cell lymphoma update. Oncology Grand Rounds, Kettering Medical Center, Dayton, Ohio 6/1/2000.

Breneman DL: Cutaneous T-cell lymphoma update. Dermatology Grand Rounds, Grandview Hospital, Dayton, Ohio 6/2/2000.

Breneman DL: Innovative treatments for cutaneous T-cell lymphoma. Dermatology Grand Rounds, Ohio State University, Columbus, Ohio 8/11/00.

Breneman DL: LGD1069 in the treatment of cutaneous T-cell lymphoma. Dermatology Grand Rounds, University of Pittsburgh, Pittsburgh, Pennsylvania 8/16/2000.

Breneman DL: Treatment of cutaneous T-cell lymphoma. Community Dermatology Consultants Program, Dayton, Ohio 8/28/2000.

Breneman DL: Treatment of cutaneous T-cell lymphoma. Central Kentucky Dermatology Society, Lexington, Kentucky 11/9/2000.

Breneman DL: Treatment of cutaneous T-cell lymphoma. Dermatology Grand Rounds, Ohio State University, Columbus, Ohio 5/10/2002.

Breneman DL: Treatment options for cutaneous T-cell lymphoma. Central Ohio Dermatological Society, Columbus, Ohio 11/4/2004.

Breneman DL: Cutaneous T-cell lymphoma: Treatment options. Wake Forest University Department of Dermatology 2005 Spring meeting, Winston-Salem, North Carolina 5/10/2005.

Presentations at Local Meetings

Dermatology Basic Science, 11/83 - "Eccrine Glands"

Dermatology Basic Science, 3/84 - "Apocrine Glands"

Dermatology Basic Science, 6/84 - "The Porphyrias"

Dermatology Basic Science, 2/85 - "Porphyria Cutanea Tarda"

Greater Cincinnati Society of Radiation Therapy Technologists, 6/86 ? "Skin Cancer"

Oncology Nursing Certification Review Course, 2/87 ? "Skin Malignancies"

Dermatology Basic Science, 4/87 ? "Clinical Research Studies"

Dermatology Grand Rounds, 11/87 ? "Bath PUVA"

Dermatology Basic Science, 3/88 ? "Mupirocin for Secondarily Infected Dermatoses"

Oncology Nursing Certification Review Course, 3/88 ? "Skin Malignancies"

Dermatology Grand Rounds, 8/88 ? "Common Cutaneous Infections"

Clinical Toxicology Journal Club, 10/88 ? "Retinoids in Dermatology"

Dermatology Grand Rounds, 12/88 ? "Bath PUVA"

American Cancer Society Professional Education Nursing Seminar, 5/89 ? "Skin Cancer

Dermatology Grand Rounds, 7/89 ? "Common Cutaneous Infections"

Oncology Nursing Certification Review Course, 1/90 ? "Skin Malignancies"

Dermatology Grand Rounds, 1/90 ? "Update on Mycosis Fungoides"

Dermatology Basic Science, 2/90 ? "Mycology I ? Saprophytic Fungi"

Dermatology Basic Science, 5/90 ? "Mycology II ? Dermatophytes"

Dermatology Basic Science, 6/90 ? "Mycology III ? Dimorphic Fungi and Yeasts"

Oncology Nursing Certification Review Course, 3/91 ? "Skin Malignancies"

Dermatology Grand Rounds, 5/91 ? "Update on Bath PUVA"

Dermatology Basic Science, 7/91 ? "Dermatophytes"

Dermatology Grand Rounds, 10/91 ? "Mycosis Fungoides ? Clinical Evaluation and Current Research"

Dermatology Basic Science, 1/92 ? "The Zygomycetes, Dematiaceous Molds, and Rapidly Growing Hyaline Molds"

Oncology Nursing Certification Review Course, 4/92 ? "Skin Malignancies"

Medical Student Skin Club, 5/92 ? "The Sun and Your Skin"

Dermatology Grand Rounds, 7/92 ? "Research Presentations"

Dermatology Grand Rounds, 3/93 ? "Cutaneous Lymphomas ? Unusual Presentations"

Oncology Nursing Certification Review Course, 4/93 ? "Skin Malignancies"

Dermatology Grand Rounds, 7/93 - "Cutaneous Lymphomas other than Mycosis Fungoides"

Dermatology Basic Science, 3/94 - "Dermatophytes"

Dermatology Basic Science, 4/94 - "Dimorphic Fungi"

Dermatology Basic Science, 5/94 - "Saprophytic Fungi"

Dermatology Grand Rounds, 6/94 - "Cutaneous T-Cell Lymphoma - Therapeutic Challenge"

Dermatology Grand Rounds, 11/94 - "Cost and Therapeutic Outcome in Cutaneous T-Cell Lymphoma"

Dermatology Grand Rounds, 3/96 - "Topical Anti-Pruritic Update"

Dermatology Basic Science, 3/96 - "The Zygomycetes, Dermatiaceous Molds, and Rapidly Growing Hyaline Molds"

Dermatology Basic Science, 3/96 - "Dermatophytes"

Dermatology Basic Science, 4/96 - "Dimorphic Fungi"

Dermatology Grand Rounds, 6/96 - "Urticaria"

Radiation Oncology Grand Rounds, 9/96 - "The Cutaneous T-Cell Lymphomas"

Dermatology Grand Rounds, 10/96 - "Evaluation of Cutaneous T-Cell Lymphomas"

Dermatology Grand Rounds, 4/97 - "Phase 1-2 Clinical Trial Supports the Safety and Efficacy of Targretin Topical Gel in the Treatment of Cutaneous T - Cell Lymphoma"

Dermatology Grand Rounds, 5/98 - "Cutaneous T-Cell Lymphoma: Support Groups and the Internet"

Dermatology Grand Rounds, 9/99 - "Update on Cutaneous T-Cell Lymphoma"

Cincinnati Oncology Group, 3/2000 - "New Treatments for Cutaneous T-Cell Lymphoma"

Dermatology Grand Rounds, 5/2000 - "New Treatments for Cutaneous T-Cell Lymphoma"

Dermatology Grand Rounds, 4/2002 – “Topical Treatment of Cutaneous T-Cell Lymphoma, Part I”

Dermatology Grand Rounds, 6/2002 – “Topical Treatment of Cutaneous T-Cell Lymphoma, Part II”

Dermatology Grand Rounds, 7/2002 – “Systemic Treatment of Cutaneous T-Cell Lymphoma, Part I”

Dermatology Grand Rounds, 9/2002 – “Systemic Treatment of Cutaneous T-Cell Lymphoma, Part II”

Dermatology Grand Rounds, 5/2004 – “Cutaneous T-Cell Lymphoma: Cost and Therapeutic Outcome”

Dermatology Grand Rounds, 7/2005 – “Classification and Staging Systems for Cutaneous T-Cell Lymphoma”

Dermatology Grand Rounds, 7/2005 – “Goal-Directed Treatment of Cutaneous T-Cell Lymphoma”

Dermatology Research Day, 1/2006 – “Clinical Research Studies in Cutaneous T-Cell Lymphoma”

Moderator at Professional Meetings

Residents' Forum, Ohio Dermatological Association 1991 annual meeting, Dayton, Ohio 9/15/91.

CLINICAL RESEARCH ACTIVITIES

Grants

Food and Drug Administration Orphan Products Award ? Principal Investigator: "A Randomized, Double?Blind Trial Comparing the Efficacy of the Combination of Tetracycline and Nicotinamide vs. Prednisone in the Treatment of Bullous Pemphigoid". (1991?1995, $94,729.00)

The Skin Cancer Foundation Henry W. Menn Award ? Co?Investigator: "Sensitive Detection of Monoclonal T?lymphocytes in Patients with Mycosis Fungoides/Sezary Syndrome". (1992, $5,000.00)

National Institutes of Health Sponsored Request for Proposal Contracts

Principal Investigator: "Evaluation of SQ 32,756 (BV?araU) versus Acyclovir in the Treatment of Localized Herpes Zoster in HIV?Infected Patients". (1993-1994)

Principal Investigator: "Evaluation of SQ 32,756 (BV?araU) versus Acyclovir in the Treatment of Localized Herpes Zoster in Immunocompromised Patients". (1993- 1995)

Physician-Initiated Investigational New Drug Research

Principal Investigator: “A Phase II Evaluation of Bexarotene Gel 1% in Patients with Mild to Moderate Plaque Psoriasis”. (2002-2003)

Cutaneous T?Cell Lymphoma (partial listing)

Principal Investigator, "Protocol for the Treatment of Mycosis Fungoides Limited to Skin and Lymph Nodes"; protocol in cooperation with the National Cancer Institute. (1988?1989)

Principal Investigator, "Protocol for the Treatment of Advanced or Refractory Mycosis Fungoides With or Without the Sezary Syndrome"; protocol in cooperation with the National Cancer Institute. (1988?1991)

Principal Investigator, "A Study to Determine the Uniformity of Cutaneous Distribution and Potential for Environmental Contamination with Topical Mechlorethamine Using Aqueous and Ointment Vehicles Commonly Used in the Preparation of Topical Mechlorethamine for the Treatment of Mycosis Fungoides". (1990)

Principal Investigator, "Multi?Modality Treatment of Patients with Intermediate Prognosis Cutaneous T?Cell Lymphoma". (1992-1997)

Principal Investigator, "Sensitive Detection of Monoclonal T?lymphocytes in Patients with Mycosis Fungoides/Sezary Syndrome". (1992?1993)

Principal Investigator, "A Double?Blind, Randomized, Vehicle? Controlled Crossover Study Evaluating the Safety and Efficacy of Topical Naloxone Lotion 0.5% in Subjects with Pruritic Mycosis Fungoides or Sezary Syndrome". (1993-1994)

Principal Investigator, "An Open Label, Compassionate Use Study Monitoring the Long Term Safety and Efficacy of Topical Naloxone Lotion, 0.5%, in Subjects with Pruritic Mycosis Fungoides or Sézary Syndrome". (1993-1994)

Co?Investigator, "Study to Determine the Laboratory Methods Most Effective in Diagnosing Blood Involvement in Patients with Mycosis Fungoides or the Sezary Syndrome". (1993?1996)

Principal Investigator, "A Double-Blind, Randomized, Vehicle-Controlled, Crossover Study to Evaluate the Safety and Efficacy of Topical Naloxone Hydrochloride Lotion, 0.2%, in the Treatment of Pruritus in Patients with Mycosis Fungoides or Sézary Syndrome". 1994)

Principal Investigator, "An Open-Label, Compassionate Use Study to Monitor the Long-Term Safety of Topically Applied Naloxone Hydrochloride Lotion, 0.2%, for the Relief of Chronic Intractable Pruritus in Patients with Mycosis Fungoides or Sézary Syndrome". (1994)

Principal Investigator, "Phase 1-2 Evaluation of Topical LGD1069 in Patients with Cutaneous T-Cell Lymphoma (Mycosis Fungoides)". (1995-1999)

Co-Investigator, "Treatment of patients with intermediate and advanced mycosis fungoides/Sézary syndrome with zidovudine (AZT) and interferon alpha". (1996-1998)

Principal Investigator, "Phase 2-3 Evaluation of Targretin^TM Capsules in Patients with Refractory or Persistent Early Stage Cutaneous T-Cell Lymphoma". (1997-1999)

Principal Investigator, "Phase 2-3 Evaluation of Targretin^TM Capsules in Patients with Refractory Advanced Stage Cutaneous T-Cell Lymphoma". (1997-1999)

Principal Investigator, "Phase 3 Evaluation of Targretin^TM Topical Gel in Patients with Refractory or Persistent Early Stage Cutaneous T-Cell Lymphoma". (1998-1999)

Principal Investigator, "Treatment Continuation of Targretin^TM Topical Gel in Patients with Persistent Early Stage Cutaneous T-Cell Lymphoma". (1999-2000)

Principal Investigator, "Treatment Continuation of Targretin® Capsules in Patients with Cutaneous T-Cell Lymphoma". (1999-2000)

Principal Investigator, "Treatment Continuation of Targretin® Topical Gel in Patients with Cutaneous T-Cell Lymphoma". (1999-2000)

Principal Investigator, "A Multicenter Phase I/II Open-Label Study of Oral BCX-34 (Peldesine) in the Treatment of Relapsed/Refractory Cutaneous T-Cell Lymphoma (CTCL)". (1999-2001)

Principal Investigator, “Phase IIb Multicenter Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Advanced Cutaneous T-Cell Lymphoma” (2005-Present)

Principal Investigator, “A Phase I, Multi-Center, Open-Label, Safety and Pharmacokinetic, Repeat-Dose Study of Oral Forodesine Hydrochloride in Patients with Refractory Cutaneous T-Cell Lymphoma” (2005-2006)

Principal Investigator, “A Continuation Clinical Trial of Oral L-001079038 in Advanced Cancers”, Merck (2006-Ongoing)

Dermatopharmacology

Principal Investigator, "A Randomized, Double?Blind Study of Zostrix Cream (0.025% Capsaicin) and Zostrix Vehicle Control in the Treatment of Moderate to Severe Pruritus in Patients Undergoing Chronic Hemodialysis". (1988)

Principal Investigator, "An Open Label Study of Zostrix Cream (0.025% Capsaicin) in the Treatment of Moderate to Severe Pruritus in Patients Undergoing Chronic Hemodialysis". (1988)

Co?Investigator, "The Study of Zostrix Cream for Pruritus in Burn Patients". (1988?1989)

Principal Investigator, "A Randomized, Open Label Trial Comparing the Efficacy of the Combination of Tetracycline and Nicotinamide Versus Prednisone in the Treatment of Bullous Pemphigoid". Approved FDA Orphan Products Division. (1989?1991)

Principal Investigator, "A Randomized, Double?Blind Trial Comparing the Efficacy of the Combination of Tetracycline and Nicotinamide vs. Prednisone in the Treatment of Bullous Pemphigoid". Approved FDA Orphan Products Division. (1992?1995)

Principal Investigator, "Potential for Isolation of Human Immuno-deficiency Virus?1 from Suction Blister Fluid in HIV+ Patients". (1993)

Co-Investigator, "A Phase IV Clinical Trial to Evaluate the Efficacy and Safety of PUVA (Psoralen and Ultraviolet A Radiation) in Patients with Psoriasis not Adequately Responsive to Topical Steroid Therapy". (1993)

Clinical Research Contracts

Principal Investigator – 200+ research protocols

Co?Investigator – 15+ research protocols

Other Clinical Research Activities

Principal Investigator, "Potential for Isolation of Human Immunodeficiency Virus?1 from Suction Blister Fluid in HIV+ patients". (1993)

Co-investigator, "A Phase IV Clinical Trial to Evaluate the Efficacy and Safety of PUVA(Psoralen and Ultraviolet A Radiation) in Patients with Psoriasis not Adequately Responsive to Topical Steroid Therapy". (1993)

Reviewer For Scientific Publications

Journal of the American Academy of Dermatology

American Family Physician

DICP ? The Annals of Pharmacotherapy

Photodermatology, Photoimmunology, and Photomedicine

The Annals of Pharmacotherapy

The Journal of Pharmacy Technology

European Journal of Dermatology

Pediatric Dermatology

The Medical Letter

Journal of Critical Illness

International Journal of Dermatology

Editorial Boards

Skin and Aging

University of Cincinnati Department of Dermatology